EGFR and glioblastoma: Overall, MGMT methylation was seen in 35% (n = 8), IDH mutations were observed in 35% (n = 8, all grade III), and EGFR amplification was seen in 44% (n = 10, all glioblastoma) of patients, consistent with the heterogenous population of malignant glioma patients.